<DOC>
	<DOCNO>NCT01851018</DOCNO>
	<brief_summary>The purpose study compare toxicities 2 external beam radiation fractionation scheme plus brachytherapy boost prostate cancer . Our current standard use 2 Gy per fraction schedule compare experimental hypofractionated 3 Gy per day approach neo adjuvant hormonal therapy . It demonstrate feasibility safety treatment regimen prostate cancer . It may also set base large randomize trial .</brief_summary>
	<brief_title>Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment</brief_title>
	<detailed_description>30 patient intermediate / extensive low risk ( core biopsy involvement &gt; 50 % ) prostate cancer ( necessitate treat nodal region ) include study . Patient stage T1 - T2 , Gleason score ≤ 7 , prostate-specific antigen ( PSA ) ≤ 20 consider . Fiducial gold marker introduce prostate 1-week CT planning . 36 gray ( Gy ) 12 fraction use intensity-modulated radiation therapy ( IMRT ) administer prostate ( margin 0,5cm ) +/- first centimeter seminal vesicle . Brachytherapy boost ( 15 Gy x 1 ) dosimetric parameter respect current standard ( Prostate V100 &gt; 90 % V150 ≤ 40 % , V200 ≤ 15 % , Urethra V125 ≤ 1 cc , Rectum V75 ≤ 1cc , Bladder V75 ≤ 1cc ) . Short course ( 4 month ) hormonal therapy ( Degarelix ) administer patient base upon recommended litterature11 , 12 . Genitourinary ( GU ) , GI Sexual toxicity self report . QOL questionnaires give patient answer . Results monitor compare currently use standard fractionation regiment . Follow-up schedule 6 week implant every 4 month first year , every 6 month second year 2 5 , yearly basis 5 year . PSA &amp; testosterone test do every 3 month first 3 year , every 6 month year 4 5 , yearly thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>30 patient intermediate / extensive low risk ( core biopsy involvement &gt; 50 % ) prostate cancer ( necessitate treat nodal region ) Patient stage T1 T2 , Gleason score ≤ 7 , PSA ≤ 20 consider patient unfit biopsy brachytherapy high low risk prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>brachytherapy</keyword>
	<keyword>hypofractionated radiation therapy</keyword>
	<keyword>hormonal therapy</keyword>
</DOC>